SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Exact Sciences Corp. – ‘8-K’ for 3/2/23

On:  Friday, 3/3/23, at 8:54am ET   ·   For:  3/2/23   ·   Accession #:  1124140-23-22   ·   File #:  1-35092

Previous ‘8-K’:  ‘8-K’ on 3/1/23 for 2/23/23   ·   Next:  ‘8-K’ on / for 3/17/23   ·   Latest:  ‘8-K’ on / for 5/8/24   ·   6 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 3/03/23  Exact Sciences Corp.              8-K:2,3,9   3/02/23   11:210K

Current Report   —   Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     48K 
 6: R1          Cover Page                                          HTML     45K 
 9: XML         IDEA XML File -- Filing Summary                      XML     11K 
 7: XML         XBRL Instance -- exas-20230302_htm                   XML     21K 
 8: EXCEL       IDEA Workbook of Financial Reports                  XLSX      8K 
 3: EX-101.DEF  XBRL Definitions -- exas-20230302_def                XML     39K 
 4: EX-101.LAB  XBRL Labels -- exas-20230302_lab                     XML     80K 
 5: EX-101.PRE  XBRL Presentations -- exas-20230302_pre              XML     39K 
 2: EX-101.SCH  XBRL Schema -- exas-20230302                         XSD     10K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               14±    20K 
11: ZIP         XBRL Zipped Folder -- 0001124140-23-000022-xbrl      Zip     22K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C:  C: 
  exas-20230302  
 i 0001124140 i false00011241402023-03-022023-03-02

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM  i 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):   i March 2, 2023
 
 i EXACT SCIENCES CORPORATION
(Exact Name of Registrant as Specified in Charter)
 
 i Delaware  i 001-35092  i 02-0478229
(State or Other Jurisdiction
of Incorporation)
 (Commission
File Number)
 (I.R.S. Employer
Identification No.)
 
 i 5505 Endeavor Lane
 i Madison,  i WI   i 53719
(Address of Principal Executive Offices)(Zip Code)
 
Registrant’s telephone number, including area code:  ( i 608)  i 284-5700
 
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 i             Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 i            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 i             Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 i            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)
Name of each exchange
on which registered
 i Common Stock, $0.01 par value per share i EXAS i The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  i 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 2.03.                     Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of the Registrant.

On March 2, 2023, Exact Sciences Corporation (the “Company”) entered into privately negotiated exchange agreements (the “Agreements”) with two holders (the “Holders”) of the Company’s 1.00% Convertible Senior Notes due 2025 (the “2025 Notes”). Pursuant to the terms of the Agreements, the Company has agreed to issue to the Holders $72,993,000 aggregate principal amount of 2.00% Convertible Senior Notes due 2030 (the "2030 Notes") in exchange for $65,833,000 aggregate principal amount of the Holders’ 2025 Notes. Accrued and unpaid interest on the Holders’ 2025 Notes will be paid by the Company in cash. The 2030 Notes will be issued pursuant to an indenture dated as of January 17, 2018 (the “Base Indenture), between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), as supplemented by the fourth supplemental indenture dated as of March 1, 2023, (the “Supplemental Indenture and together with the Base Indenture, the Indenture).
The 2030 Notes will be issued by the Company without registration in reliance on the exemption provided by Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”). The 2030 Notes will mature on March 1, 2030 (the “Maturity Date”), unless earlier repurchased or converted. The 2030 Notes are senior unsecured obligations of the Company and bear interest at a rate of 2.00% per year, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2023.
Prior to September 1, 2029, the 2030 Notes will be convertible only upon the occurrence of certain events specified in the Indenture and during certain periods, and thereafter, until the close of business on the second scheduled trading day immediately preceding the Maturity Date. The 2030 Notes will be convertible into cash, shares of the Company’s common stock (plus, if applicable, cash in lieu of any fractional share), or a combination of cash and shares of the Company’s common stock, at the Company’s election.
The Company may not redeem the 2030 Notes prior to the Maturity Date. If a “fundamental change” (as defined in the Indenture) occurs prior to the Maturity Date, subject to certain conditions, the Holder may require the Company to repurchase for cash all or any portion of their 2030 Notes at a repurchase price equal to 100% of the principal amount of the 2030 Notes to be repurchased plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date.
The conversion rate for the 2030 Notes is initially 12.3724 shares per $1,000 principal amount of 2030 Notes, which is equivalent to an initial conversion price of approximately $80.825 per share of common stock. The conversion rate is subject to adjustment upon the occurrence of certain specified events but will not be adjusted for accrued and unpaid interest. In addition, holders of the 2030 Notes who convert their 2030 Notes in connection with a “make-whole fundamental change” (as defined in the Indenture), will, under certain circumstances, be entitled to an increase in the conversion rate.
The Indenture contains customary events of default including: (1) the Company’s failure to pay any interest on the 2030 Notes for 30 calendar days after the date when due; (2) the Company’s failure to pay when due (a) the principal of the 2030 Notes or (b) the fundamental change repurchase price payable (as defined in the Indenture) in respect of the 2030 Notes; (3) the Company’s failure to comply with its obligations to convert any 2030 Notes in accordance with the Indenture for a period of five business days following the scheduled settlement for such conversion; (4) the Company’s failure to provide notice as required pursuant to the Indenture in the event of certain specified corporate transactions or events; (5) the Company’s failure to perform or its breach of any covenant or warranty of the Company contained in the 2030 Notes or the Indenture for a period of 60 consecutive calendar days after written notice of such failure, requiring the Company to remedy the same, shall have been given (a) to the Company by the Trustee or (b) to the Company and the Trustee by the holders of at least 25% in aggregate principal amount of the 2030 Notes then outstanding; and (6) certain events of bankruptcy, insolvency or reorganization with respect to the Company.
If an event of default occurs and is continuing, the Trustee by notice to the Company, or the holders of at least 25% in aggregate principal amount of 2030 Notes then outstanding by notice to the Company and the Trustee, may declare the principal of all of the then outstanding 2030 Notes to be due and payable.
The Indenture provides that the Company may, without the consent of the holders of the 2030 Notes, consolidate with, merge into or transfer all or substantially all of its consolidated assets to any corporation organized under the laws of the United States or any of its political subdivisions provided that: (1) the surviving entity assumes all of the Company’s obligations under the Indenture and the 2030 Notes, as provided in the Indenture; (2) immediately after giving effect to such transaction, no default or event of default shall have occurred and be continuing; and (3) if the Company will not be the resulting or surviving corporation from the consolidation, merger or transfer, an officer’s certificate and an opinion of counsel, each stating that the consolidation, merger or transfer complies with the Indenture, have been delivered to the Trustee.
2


The foregoing description of the Indenture does not purport to be complete and is qualified in its entirety by reference to the full text of the Base Indenture and Supplemental Indenture, which are incorporated by reference as Exhibit 4.1 and Exhibit 4.2, respectively, hereto. The form of the 2030 Notes issued pursuant to the Indenture is attached as an exhibit to the Supplemental Indenture and the terms and conditions thereof are incorporated by reference herein.
Item 3.02.                     Unregistered Sale of Equity Securities.

The information set forth in Item 2.03 of this Current Report on Form 8-K is incorporated herein by reference.

Item 9.01.                     Financial Statements and Exhibits.
 
Exhibits

The exhibits to this Current Report on Form 8-K are listed below and incorporated herein by reference.
  
Exhibit No. Exhibit Description
   
3


SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 EXACT SCIENCES CORPORATION
   
Date: March 3, 2023By:/s/ Jeffrey T. Elliott
  Jeffrey T. Elliott
  Executive Vice President, Chief Financial Officer and Chief Operating Officer

4

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
3/1/30
9/1/29
9/1/23
Filed on:3/3/23
For Period end:3/2/234
3/1/23144,  4,  8-K
1/17/184,  8-K
 List all Filings 


4 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/08/24  Exact Sciences Corp.              424B7                  2:522K
 8/01/23  Exact Sciences Corp.              S-8         8/01/23    4:106K
 5/25/23  Exact Sciences Corp.              S-3ASR      5/25/23    6:771K
 3/17/23  Exact Sciences Corp.              424B7                  2:659K


2 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/01/23  Exact Sciences Corp.              8-K:1,2,3,8 2/23/23   13:859K
 1/17/18  Exact Sciences Corp.              8-K:1,8,9   1/11/18    6:1.6M                                   Toppan Merrill/FA
Top
Filing Submission 0001124140-23-000022   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., May 17, 11:41:25.1pm ET